Novo Nordisk (NYSE: NVO) Reports Strong Earnings and Raises 2026 Guidance

The Danish drugmaker Novo Nordisk (NYSE: NVO) is in focus after its November 4, 2026, earnings report arrives before the market opens. The company sells diabetes and obesity treatments, including Wegovy, in markets where it competes with other drugmakers.

Novo Nordisk reports earnings per share of $0.89, above the $0.73 estimate. Earnings per share show how much profit the company earns for each share. The $0.16 difference means its reported profit per share is higher than analysts expect.

Revenue reaches $11.86 billion, compared with an estimate of $11.08 billion. That is a $0.78 billion difference. Revenue measures sales before expenses, so the result shows stronger sales than expected but does not, on its own, show how much profit those sales produce.

The company also raises its 2026 guidance, or its forecast for the year. It cites a better outlook for its obesity and diabetes drugs, particularly outside the U.S., as highlighted by The Wall Street Journal. The report says the rollout of its Wegovy weight-loss pill continues. Reuters also highlights that third-quarter profit exceeds forecasts.

Novo Nordisk has a trailing price-to-earnings ratio of 10.17, meaning its share price is about 10 times its earnings over the past year. Its current ratio is 0.87, which compares short-term assets with short-term liabilities. These measures give investors more context for the earnings report but do not show how much the new guidance changes expected profit.